info.evaluate.comPharma commercial intelligence, news & analysis | Evaluate

Pharma commercial intelligence, news & analysis | Evaluate Search Search Close this search box. Subscriber Log In Menu Subscriber Log In Search Search Subscriber Log In How We Help Asset Screening Competitive Landscape Analysis Commercial Opportunity Assessment Company Profiling Deal Benchmarking Market Opportunity Sizing Solutions Products Evaluate Omnium Evaluate Pharma BioSciDB Japan Drug Forecasts Evaluate Epi Europe Drug Forecasts Evaluate Medtech CDMO Intelligence Real-World Data Competitive Intelligence Consulting & Analytics Consulting & Analytics Data Feeds Resources News & Events Thought Leadership Webinars About Careers Meet Our Team What Sets Us Apart Contact Menu How We Help Asset Screening Competitive Landscape Analysis Commercial Opportunity Assessment Company Profiling Deal Benchmarking Market Opportunity Sizing Solutions Products Evaluate Omnium Evaluate Pharma BioSciDB Japan Drug Forecasts Evaluate Epi Europe Drug Forecasts Evaluate Medtech CDMO Intelligence Real-World Data Competitive Intelligence Consulting & Analytics Consulting & Analytics Data Feeds Resources News & Events Thought Leadership Webinars About Careers Meet Our Team What Sets Us Apart Contact Are orphan drugs losing their sparkle? For more than a decade, orphan drugs’ growth has outpaced that of non-orphan prescription drugs. But the growth gap is narrowing… DOWNLOAD THE NEW REPORT NOW How can CDMOs succeed in 2024 and beyond? Watch our webinar to explore key growth drivers and top opportunities for CDMOs in 2024 and beyond. WATCH NOW Real World Data Real-world data (RWD) is a game changer when it comes to understanding how healthcare operates in reality. Medical and pharmacy claims, lab tests and results, electronic health records, and clinical pathways combine to provide an incredibly granular glimpse into the patient journey. LEARN MORE Q1 Round Up: Situation Normal? As 2023 drew to a close, the biopharma industry began to shake off its previous struggles. Has this positive momentum carried into the early months of this year? READ NOW Competitive Intelligence Strategic competitive intelligence in the pharma industry is a crucial but time consuming and complex task. Find out how Evaluate can provide a technology-enabled extension of your team to ensure your people are free to focus on the areas that will achieve your goals. LEARN MORE Evaluating Neurology Evaluate provides a snapshot of some of the most interesting players in the field, looking at their pipeline highlights, marketed drugs and what makes them ones to watch. DOWNLOAD Evaluating the Cell and Gene Therapy Landscape Explore the present and future of cell and gene therapies in Evaluate’s latest report. Our analysis focuses on market growth, leading players and primary areas of focus. We also investigate the competitive dynamics between biotech and big pharma, trends in dealmaking and future revenue drivers. DOWNLOAD ADC Antibody-drug conjugates (ADCs) are the hottest real estate in oncology, attracting billions from Big Pharma. What’s all the fuss about? Find out in our new report, featuring insights on the market landscape and highlights of some of the most interesting players in the space. DOWNLOAD NOW Evaluate radically transforms your confidence in strategic portfolio decisions. In biopharma, making the right decisions has an incredible impact on patients’ lives. Making those decisions requires a deep understanding of your market; from identifying opportunities and mitigating risk to evaluating assets and pipelines. Evaluate provides a complete and dynamic view of the pharmaceutical market, with innovative solutions that bring together technology, real world data, and deep expertise to help you make portfolio decisions that drive growth. HOW WE HELP Connected data gives you a clearer picture. Evaluate gives you the understanding and time you need to drive better decisions. Market Opportunity Sizing Identify the market that offers the greatest potential for your business so you can confidently prioritise assets and allocate resources. Find Out More Commercial Opportunity Assessment Develop a robust view of potential partners and licensing opportunities to boost your pipeline and amplify your commercial success. Find Out More Competitive Landscape Analysis Build a clear analysis of the evolving landscape – market dynamics, emerging trends and key players – and make strategic moves that strengthen your position. Find Out More Company Profiling Monitor key companies so you can track potential partners and competitors and find opportunities in a constantly changing environment. Find Out More Asset Screening Obtain a clear and unbiased assessment of asset value to drive licensing decisions and ensure you invest in assets with the highest potential for success. Find Out More Deal Benchmarking Bring confidence to your allocation strategy with timely external benchmarking data across the R&D landscape. Find Out More We collect, collaborate and connect. OUR SOLUTIONS Insight at Your Fingertips Access our world-class forecasting, analysis and machine learning-driven insight to help you reduce risk, maximise returns, and make smarter decisions about your portfolio strategy. LEARN MORE MARKET REPORTS Trends & Analysis Dive into our market reports covering sector performance and valuation, emerging trends and global forecasts. Stay ahead of the competition with the latest developments that impact your portfolio strategy. LEARN MORE OUR SERVICES Consulting & Analytics Tap into our expertise and reach your goals with our collaborative team of specialists, providing technology-enabled consulting, strategic commercial insights, and recommendations across the product lifecycle. LEARN MORE Latest Solutions & Insights Understand the context. Data-driven insights and analysis for the pharma, biotech and medtech sectors. May 7, 2024 What’s the Deal? Navigating the Complex World of Pharma Business Development 2024 has the potential to be a year full of partnering opportunities, driven by the much-discussed patent cliff as some of the biggest-selling drugs in history are set to lose ... April 30, 2024 Meet the Team: Andrew Ward If you missed the recent news, Evaluate recently acquired J+D Forecasting, a provider of brilliant forecasting solutions to pharma and biotech companies. Andrew Ward has been with the J+D team ... April 9, 2024 US Health Systems: A Driving Force for Digital Health The US Healthcare system is a vast, unwieldy beast that requires significant navigation by any company in the healthcare space. Whether you’re a Big Pharma, a small biotech or an ... April 4, 2024 Next Generation Dealmaking with Evaluate and Inpart Dealmaking is a hallmark of the pharma industry. Whether to access innovative therapies, expand into new areas or fill a gap left from a failure in the clinic, pipelines need ... March 28, 2024 Meet the Evaluate Team: Markella Kordoyanni Markella is part of Evaluate’s competitive intelligence (CI) consulting practice, where she works on a wide range of projects to support CI teams in pharma companies to ensure they stay ... March 27, 2024 Competitive Intelligence Insights: Cell & Gene Therapy The number of cell and gene therapy (C>)-based treatments in development has increased significantly over the last two decades and can be expected to continue, driven by the modality-specific market ... Ready to learn more? Contact us today to get started. Area of Interest Call Back Careers Demo Evaluate Consulting Services Evaluate Products & Services Media Enquiry Other Country United States United Kingdom Canada American Samoa Andorra Anguilla Antigua and Barbuda Argentina Aruba Bahamas Barbados Belarus Belize Bermuda Bolivia, Plurinational State of Bonaire, Sint Eustatius and Saba Bouvet Island Brazil Cayman Islands Chile Colombia Comoros Costa Rica Croatia Cuba Curacao Dominica Dominican Republic Ecuador El Salvador Falkland...